Приказ основних података о документу

dc.creatorKurćubić, Ivana
dc.creatorVajić, Una-Jovana
dc.creatorCvijić, Sandra
dc.creatorCrevar-Sakač, Milkica
dc.creatorBogavac-Stanojević, Nataša
dc.creatorMiloradović, Zoran
dc.creatorMihajlović-Stanojević, Nevena
dc.creatorIvanov, Milan
dc.creatorKaranović, Danijela
dc.creatorJovović, Đurđica
dc.creatorĐuriš, Jelena
dc.date.accessioned2021-11-24T12:16:40Z
dc.date.available2021-11-24T12:16:40Z
dc.date.issued2021
dc.date.issued2021
dc.identifier.issn0378-5173
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/3990
dc.description.abstractThe objective of this study was to formulate extended-release mucoadhesive buccal tablets of propranolol hydrochloride in order to provide a prolonged absorption of propranolol hydrochloride from the buccal mucosa and to reduce presystemic metabolism and thus provide a better therapeutic effect. Besides, the aim was to perform comparative in vivo pharmacokinetic and hemodynamic studies of the developed extended-release (ER) propranolol hydrochloride 10 mg mucoadhesive buccal tablets and commercial immediate-release (IR) propranolol hydrochloride 10 mg tablets in spontaneously hypertensive rats. Formulation with 15% polyethylene oxide showed the highest degree of propranolol hydrochloride permeation, satisfactory mucoadhesiveness, and extended-release of propranolol hydrochloride, thus it was selected for further in vivo study. The pharmacokinetic study in rats showed the superiority of ER mucoadhesive buccal tablets over IR tablets in terms of propranolol hydrochloride absorption extent (AUC values: 70.32 ± 19.56 versus 31.69 ± 6.97 μg⋅h/mL), although lower maximum plasma propranolol hydrochloride concentration (Cmax) was achieved. However, no statistically significant difference was observed in Cmax between these treatments. The hemodynamic study showed that ER mucoadhesive buccal tablets provide a more pronounced decrease primarily in heart rate, but also in systolic and diastolic arterial pressure, as well as a longer heart rate reduction compared to IR tablets.
dc.publisherElsevier B.V.
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200161/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200015/RS//
dc.rightsrestrictedAccess
dc.sourceInternational Journal of Pharmaceutics
dc.subjectSpontaneously hypertensive rats
dc.subjectEssential hypertension
dc.subjectExtended-release
dc.subjectMucoadhesive buccal tablets
dc.subjectPharmacokinetics
dc.subjectPropranolol hydrochloride
dc.titleMucoadhesive buccal tablets with propranolol hydrochloride: Formulation development and in vivo performances in experimental essential hypertension
dc.typearticle
dc.rights.licenseARR
dc.citation.volume610
dc.citation.rankM21
dc.identifier.wos000718955600008
dc.identifier.doi10.1016/j.ijpharm.2021.121266
dc.identifier.scopus2-s2.0-85118892119
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу